

Lenacapavir as part of a Combination Regimen in Treatment-Naïve People with HIV: Week 54 Results




Samir Gupta¹, James Sims², Cynthia Brinson³, Daniel Coulston⁴, Godson Oguchi⁵, Criag Dietz⁶, Angela S Y Liu⁷, Laurie VanderVeen⁷, Hadas Dvory-Sobol⁷, Martin S Rhee⁷, Jared Baeten⁷, Wayne Paul⁸, Ellen Koenig⁹

¹Indiana University, Indianapolis, Indiana, ²St. Hope Foundation, Bellaire, Texas, ³Central Texas Clinical Research, Austin, Texas, ⁴MultiCare Rockwood HIV Critical Care Clinic, Spokane, Washington, ⁵Midland Florida Clinical Research Center, LLC, Deland, Florida, ⁶Kansas City Care Health Center, Kansas City, Missouri, ⁷Gilead Science Inc, Foster City CA US, ⁸Gilead Sciences Pty Ltd Melbourne AUS, ⁹Instituto Dominicano de Estudio Virologicos – IDEV, Santo Domingo, Dominican Republic



Introduction

LEN Targets Multiple Stages of HIV Replication Cycle




EC₅₀, half-maximal effective concentration.

- Lenacapavir (LEN, GS-6207) is a long-acting first-in-class inhibitor of HIV-1 capsid protein
 - In clinical development for treatment and prevention of HIV-1 infection
- Highly potent activity (EC₅₀: 50–100 pM), with a low clearance and slow release kinetics¹
 - Can be administered orally (daily or weekly) or subcutaneously (every 6 months)²⁻⁴
- CALIBRATE was designed to generate exploratory clinical data to support the future development of LEN-containing regimens

	Phase 2/3 in heavily Tx-experienced people with HIV ^{5,6}	LEN + OBR	Week 52	83% virologic suppression (CROI 2022) ⁷
	Phase 2 in Tx-naïve people with HIV ⁸	LEN + F/TAF	Week 28	94% virologic suppression

F/TAF, emtricitabine/tenofovir alafenamide; OBR, optimised background regimen; Tx, treatment.

Study Design




*LEN oral lead-in (600 mg on Days 1 and 2, 300 mg on Day 8) followed by LEN SC 927 mg on Day 15; F/TAF 200/25 mg. †Participants in TG 1 and 2 will need HIV-1 RNA results <50 copies/mL at Weeks 16 and 22 to initiate either TAF 25 mg or BIC 75 mg at Week 28; those with HIV-1 RNA ≥50 copies/mL will discontinue study at Week 28; ‡LEN 600 mg on Days 1 and 2, followed by LEN 50 mg from Day 3; F/TAF 200/25 mg; §B/F/TAF 50/200/25 mg.

ARV, antiretroviral; BIC, B, bictegravir; BL, baseline; OD, once daily; Q6M, every 6 months; SC, subcutaneous; TG, treatment group.

Baseline Characteristics

	LEN Total			B/F/TAF	Overall N=182
	TG 1 n=52	TG 2 n=53	TG 3 n=52	TG 4 n=25	
Age, median (range), years	31 (19, 61)	28 (19, 56)	28 (19, 72)	29 (21, 61)	29 (19, 72)
Sex, % female at birth	10	2	12	0	7
Race, % Black	46	45	60	64	52
Ethnicity, % Hispanic/Latinx	48	40	46	48	45
HIV-1 RNA, median log ₁₀ copies/mL	4.27	4.32	4.53	4.37	4.37
Q1, Q3	3.77, 4.63	3.96, 4.74	3.82, 4.83	4.09, 4.77	3.86, 4.74
>100,000 copies/mL, %	10	17	17	16	15
CD4 count, median cells/μL	404	450	409	482	437
Q1, Q3	320, 599	332, 599	301, 600	393, 527	332, 599
<200 cells/μL, %	0	2	6	0	2

Efficacy at Week 54 (FDA Snapshot)




³ participants (2 in TG 1 and 1 in TG 2) discontinued due to not meeting the protocol criteria of having HIV-1 RNA <50 copies/mL prior to Week 28; [†] 1 participant discontinued on Day 2; [‡] 2 of the 3 participants with HIV-1 RNA ≥50 copies/mL at Week 54 were suppressed in subsequent visit.

- In the pooled SC LEN group (TG 1+2): initially in combination with F/TAF, then with TAF or BIC, 88% (92/105) achieved and maintained virologic suppression at Week 54

Efficacy at Week 54 (FDA Snapshot)

Among Participants who were Virologically Suppressed at Week 28



[†] 1 participant discontinued due to not meeting the protocol criteria of having HIV-1 RNA <50 copies/mL prior to Week 28; 1 participant discontinued on Day 2.

- In the pooled SC LEN group (TG 1+2): initially in combination with F/TAF, then with TAF or BIC, among participants who were virologically suppressed at Week 28, 93% (91/98) maintained virologic suppression at Week 54


References: 1. Link JO, et al. Nature 2020;584:614-8; 2. Begley R, et al. AIDS 2020, abstr PEB0265; 3. Begley R, et al. CROI 2020, abstr 470; 4. Daar E, et al. CROI 2020, abstr 469; 5. Segal-Maurer S, et al. CROI 2021, abstr 127; 6. Molina J-M, et al. IAS 2021, abstr OALX01LB02; 7. Ogbuagu O, et al. CROI 2022, abstr 1047; 8. Gupta SK, et al. IAS 2021, abstr OALB0302; Link JO, et al. Nature 2020;584:614-8; Bester SM, et al. Science 2020;370:360-4

Acknowledgments: We extend our thanks to: The study participants and their families. Participating study investigators and staff. Dominican Republic: E Koenig/United States: P Benson; DS Berger; M Berhe; C Brinson; P Cook; DR Coulston; GE Crofoot; FA Cruickshank; D Cunningham; E DeJesus; C Dietz; V Drelichman; E Gardner; A Gaur; D Goldstein; SK Gupta; D Hagens; R Hengel; T Hodge; C-B Hsiao; A Khalsa; CA Kinder; P Kumar; C McDonald; A Mills; JO Morales-Ramirez; C Newman; G Oguchi; O Osiyemi; MN Ramgopal; PJ Ruane; W Sanchez; JL Santana-Bagur; L Santiago; A Scribner; J Sims; GI Sinclair; JL Stephens; M Wohlfeller; AK Wurapa
This study was funded by Gilead Sciences, Inc., Editorial and production assistance were provided by BioScience Communications, New York, NY, funded by Gilead.


Results

Participants with HIV-1 RNA <50 copies/mL by Visit

Missing = Failure (On Treatment)



Changes in CD4



- Baseline CD4 of the overall study population: median 437 cells/μL

Resistance Analysis*

Participants, n	TG 1 n=52	TG 2 n=53	TG 3 n=52	TG 4 n=25
Participants meeting the resistance testing criteria	1	1	3	1
Emergent LEN resistance	0	1	1	0

*Genotypic and phenotypic resistance testing performed on any participants with confirmed HIV-1 RNA ≥50 copies/mL and <1 log₁₀ HIV-1 RNA reduction from Day 1 at the Week 10 visit, at any visit after achieving HIV-1 RNA <50 copies/mL and a rebound to ≥50 copies/mL, and at any visit, with >1 log₁₀ increase from the nadir; CA, HIV capsid; INSTI, integrase strand transfer inhibitor; NRTI, nucleotide reverse transcriptase; RT, reverse transcriptase.

- Emergent LEN resistance in 2/157 (1.5%) participants
 - One participant in TG 2 developed Q67H+K70R (LEN fold change=20) in CA at Week 10, preceded by M184M/I in RT (IDWeek 2021)[†]
 - Pattern of mutation emergence suggests incomplete adherence to F/TAF
 - One participant in TG 3 developed Q67H (LEN fold change=7) in CA at Week 54
 - Non-adherence to F/TAF as assessed by pill count and drug levels
 - Both participants later re-suppressed on a regimen of INSTI + 2 NRTI

[†]Previously presented (Gupta SK, et al. IAS 2021, abstr OALB0302; VanderVeen L, et al. IDWeek 2021, oral 73).

Adverse Events (excluding ISRs)

≥10% Participants in LEN total, %	LEN Total TG 1+2+3 n=157	B/F/TAF TG 4 n=25
Headache	13%	12%
Nausea	13%	4%
COVID-19	10%	12%

- No SAEs related to study drug
- No Grade 4 AEs related to study drug
- No discontinuations due to non-ISR AEs
- Gastrointestinal AEs: SC LEN (TG 1+2) vs oral LEN (TG 3)
 - Nausea: 14% vs 12%
 - Diarrhoea: 7% vs 10%
 - Vomiting: 4% vs 8%

ISR, injection site reaction; SAE, serious adverse event.

Injection Site Reactions

ISR Types*	After 1st SC Dose at Week 1 n=103 [†]	After 2nd SC dose at Week 26 n=95 [†]	Median duration (days)
Swelling	14%	12%	11
Erythema	14%	18%	5
Pain	15%	9%	4
Nodule	11%	8%	195
Induration	9%	6%	202

*Includes those >5% at both Weeks 1 and 26; [†]TG 1+2 (ie, those who received ≥1 dose of SC LEN and still on study or last study date in 2-week interval).

- Mostly Grade 1 or 2 ISRs
 - One Grade 3 ISR (nodule) after the second SC dose
- Three participants discontinued due to ISRs:
 - Two due to induration (both Grade 1, after the first SC dose)
 - One due to erythema and swelling (Grade 1, after the second SC dose)

Laboratory Abnormalities

Participants, %	LEN Total TG 1+2+3 n=157	B/F/TAF TG 4 n=25
Any Grade 3 or 4 lab abnormality ≥5% in LEN total	25%	24%
Low creatinine clearance/eGFR*	8%	12%
High creatine kinase	7%	4%

*Per Division of AIDS scale, Grade 3 creatinine clearance is <30 mL/min or 30–50% decrease from baseline. eGFR, estimated glomerular filtration rate.

- No clinically relevant Grade 3 or 4 lab abnormalities
- No discontinuations associated with Grade 3 or 4 lab abnormalities

Conclusions

- In treatment naïve people with HIV, subcutaneous lenacapavir (LEN), initially in combination with F/TAF and later with oral TAF or BIC, achieved and maintained high rates of virologic suppression through 1 year (90% and 85%, respectively)
 - Oral LEN in combination with F/TAF had similar efficacy (85%)
- LEN was well tolerated; discontinuations due to adverse events were infrequent
- These Phase 2 data support the ongoing evaluation of LEN for treatment and prevention of HIV-1 infection
 - In heavily treatment-experienced people with HIV in the ongoing CAPELLA study
 - In treatment-naïve and -experienced people with HIV in combination with other agent(s)
 - In people who could benefit from pre-exposure prophylaxis (PrEP)